A strange thing about this treatment: the criteria that let you start it are the criteria you eventually stop meeting, and the rules were written for the first situation rather than the second.<\/p>\n
Here is what actually happens, and what the conversation should cover.<\/p>\n
Prescribing criteria for these medications are built around BMI thresholds, usually a BMI of 30 or above, or 27 or above with a weight-related condition. Insurance criteria are frequently stricter and sometimes require you to keep meeting them.<\/p>\n
So someone who starts at 34 and reaches 24 has, on paper, stopped qualifying for the thing that got them there. That is a genuine administrative and clinical tension rather than a misunderstanding.<\/p>\n
What it is not is a cliff edge that arrives without warning. It is a conversation you can have in advance, and having it early is the whole point of this article.<\/p>\n
This is the part that matters most, because it is what the decision should turn on.<\/p>\n
In the STEP 4 trial, people who had already lost weight on semaglutide were randomized either to continue it or to switch to placebo. Those who continued went on losing modestly and held what they had. Those who switched to placebo regained.<\/p>\n
That is the clearest available statement of the issue: for many people the medication is doing ongoing work rather than having completed a job. Stopping is not the natural end of a course of treatment, it is a change in treatment.<\/p>\n
Which means the question “am I done” is better framed as “what does maintenance look like for me.”<\/p>\n
Options exist between full dose and nothing, and people often do not know that.<\/p>\n
Staying at your current dose.<\/strong> Simplest, and for some people correct.<\/p>\n A lower maintenance dose.<\/strong> Many people hold their weight on less than they needed to lose it. This is a legitimate thing to explore, and it addresses cost and side effects at the same time.<\/p>\n A longer interval,<\/strong> in some circumstances and with provider input, though this is not a decision to make yourself. Stretching the interval on your own is a reliable way to get worse appetite control and returning side effects.<\/p>\n A planned stop with a maintenance plan.<\/strong> Some people do this and it works. It works better when it is planned and monitored than when it happens by default.<\/p>\n What is not on the list is continuing to push for more loss because you are still losing. Our guide on when to increase your tirzepatide dose<\/a> covers how dose decisions are meant to work, and at a normal BMI the direction of the conversation should usually be down or level rather than up.<\/p>\n The best time to raise this is when you can see it coming, not when your next refill is refused.<\/p>\n Worth asking your prescriber:<\/p>\n If cost or coverage is the constraint rather than clinical judgment, say so directly. That is a different problem with different answers, and providers can often do something with a specific constraint.<\/p>\n Consider this scenario: someone reaches their goal and finds out at the pharmacy that their plan no longer considers them eligible. They have no supply, no plan, and no appointment for three weeks. Everything that follows is worse than it needed to be, and the conversation that would have prevented it was available two months earlier, when the trajectory was already obvious.<\/p>\n Some people asking this are not worried about being stopped. They are hoping to keep going.<\/p>\n If you are at a normal BMI and want to keep losing, that is worth being honest with yourself and your provider about. There is a difference between wanting to hold what you have gained and wanting the number to keep falling, and the second one is worth examining rather than acting on.<\/p>\n Signals that it has tipped somewhere unhelpful: feeling anxious about the medication being stopped for reasons that are not about health, being pleased by how little you are eating, weight coming off faster than you or your provider intended, or hiding your intake or your weight from people.<\/p>\n And the physical cluster that says intake has gone too low, whatever the motivation: persistent fatigue that sleep does not fix, feeling cold when others are comfortable, hair shedding, dizziness on standing, losing strength.<\/p>\n None of that is a reason for shame and all of it is a reason to say something. It comes up often enough that nobody will find it surprising.<\/p>\n Know your trajectory.<\/strong> If you can see a normal BMI coming in a few months, that is when to raise it. Our guide on tracking your progress<\/a> covers what is worth recording, and the rate of change is the part that tells you when the conversation is due.<\/p>\n Do not stockpile or stretch in anticipation.<\/strong> Stretching doses to build a buffer produces worse control and returning side effects.<\/p>\n Do not stop abruptly if it comes to that.<\/strong> A planned stop is a manageable thing and an unplanned one is not. Our guide on taking a break and restarting<\/a> covers what to expect, including why restarting later means stepping back up rather than resuming where you left off.<\/p>\n Ask about a lower dose before assuming it is all or nothing.<\/strong><\/p>\n Eligibility criteria were written for starting treatment and you will eventually stop meeting them, which is a real tension rather than a misunderstanding. The evidence says continuing holds weight and switching to placebo brings it back, so the useful question is what maintenance looks like rather than whether you are finished. There is middle ground: a lower maintenance dose is often enough. Raise all of this a few months before you get there rather than at the pharmacy counter. And if what you actually want is to keep losing past a healthy weight, that is the more important conversation of the two.<\/p>\nHave the conversation before you get there<\/h2>\n
\n
The other version of this question<\/h2>\n
What to do now<\/h2>\n
The short version<\/h2>\n